Promising therapeutic effects of sodium tanshinone IIA sulfonate towards pulmonary arterial hypertension in patients

Journal of Thoracic Disease

Volumn 5, Issue 2, 2013, Pages 169-172

  Wang, Jian ^a   Lu, Wenju ^a   Wang, Wei ^a   Zhang, Nuofu ^a   Wu, Hua ^a   Liu, Chunli ^a   Chen, Xiuqing ^a   Chen, Yonghua ^a   Chen, Yuqin ^a   Jiang, Qian ^a   Xu, Lei ^a   Tian, Lichun ^a   Ran, Pixin ^a   Zhong, Nanshan ^a  

^a GUANGZHOU MEDICAL UNIVERSITY   (China)

Author keywords

Pulmonary arterial hypertension; Pulmonary hypertension; Tanshinone iia sulfonate

Indexed keywords

PLANT MEDICINAL PRODUCT; TANSHINONE IIA SULFONIC ACID; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; ARTICLE; BORG DYSPNEA SCORE; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG EFFICACY; DRUG RESPONSE; FEMALE; FUNCTION TEST; HUMAN; LUNG ARTERY PRESSURE; MALE; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; PHYSICAL CAPACITY; PULMONARY HYPERTENSION; SIX MINUTE WALKING DISTANCE; SYSTOLIC BLOOD PRESSURE; TREATMENT OUTCOME;

EID: 84876810207     PISSN: 20721439     EISSN: 20776624     Source Type: Journal    
DOI: 10.3978/j.issn.2072-1439.2013.02.04     Document Type: Article

References (21)

1. Task Force for Diagnosis and Treatment of Pulmonary Hypertension of European Society of Cardiology (ESC), European Respiratory Society (ERS), International Society of Heart and Lung Transplantation (ISHLT), et al. Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Respir J 2009;34:1219-63.
2. Benza RL, Miller DP, Gomberg-Maitland M, et al. Predicting survival in pulmonary arterial hypertension: insights from the Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management (REVEAL). Circulation 2010;122:164-72.
3. Humbert M, Sitbon O, Simonneau G. Treatment of pulmonary arterial hypertension. N Engl J Med 2004;351:1425-36.
4. Humbert M, Cabane J. Successful treatment of systemic sclerosis digital ulcers and pulmonary arterial hypertension with endothelin receptor antagonist bosentan. Rheumatology (Oxford) 2003;42:191-3.
5. Patel R, Aronow WS, Patel L, et al. Treatment of pulmonary hypertension. Med Sci Monit 2012;18:RA31-9.
6. Barst RJ, Gibbs JS, Ghofrani HA, et al. Updated evidence-based treatment algorithm in pulmonary arterial hypertension. J Am Coll Cardiol 2009;54:S78-84.
7. Kramer MR. Combination treatment in pulmonary arterial hypertension. Harefuah 2011;150:383-8, 417.
8. Levinson AT, Klinger JR. Combination therapy for the treatment of pulmonary arterial hypertension. Ther Adv Respir Dis 2011;5:419-30.
9. Abraham T, Wu G, Vastey F, et al. Role of combination therapy in the treatment of pulmonary arterial hypertension. Pharmacotherapy 2010;30:390-404.
10. Kähler CM. Combination therapy for the treatment of pulmonary arterial hypertension. Dtsch Med Wochenschr 2009;134:S181-2.
11. Benza RL, Rayburn BK, Tallaj JA, et al. Treprostinil-based therapy in the treatment of moderate-to-severe pulmonary arterial hypertension: longterm efficacy and combination with bosentan. Chest 2008;134:139-45.
12. Jiang WD, Yu YZ, Liu WW, et al. Effects of sodium tanshinone II-A sulfonate and propranolol on coronary collaterals in acutely infarcted dogs (author's transl). Zhongguo Yao Li Xue Bao 1981;2:29-33.
13. Liu J, Morton J, Miedzyblocki M, et al. Sodium tanshinone IIA sulfonate increased intestinal hemodynamics without systemic circulatory changes in healthy newborn piglets. Am J Physiol Heart Circ Physiol 2009;297:H1217-24.
14. Zhou L, Zuo Z, Chow MS. Danshen: an overview of its chemistry, pharmacology, pharmacokinetics, and clinical use. J Clin Pharmacol 2005;45:1345-59.
15. Feng J, Zheng Z. Effect of sodium tanshinone II A sulfonate on cardiac myocyte hypertrophy and its underlying mechanism. Chin J Integr Med 2008;14:197-201.
16. Zhou D, Liang Q, He X, et al. Changes of c-fos and c-jun mRNA expression in angiotensin II-induced cardiomyocyte hypertrophy and effects of sodium tanshinone IIA sulfonate. J Huazhong Univ Sci Technolog Med Sci 2008;28:531-4.
17. Yang Y, Cai F, Li PY, et al. Activation of high conductance Ca(2+)-activated K(+) channels by sodium tanshinoneII-A sulfonate (DS-201) in porcine coronary artery smooth muscle cells. Eur J Pharmacol 2008;598:9-15.
18. Shang Q, Xu H, Huang L. Tanshinone IIA: A Promising Natural Cardioprotective Agent. Evid Based Complement Alternat Med 2012;2012:716459.
19. Wang J, Dong MQ, Liu ML, et al. Tanshinone IIA modulates pulmonary vascular response to agonist and hypoxia primarily via inhibiting Ca2+ influx and release in normal and hypoxic pulmonary hypertension rats. Eur J Pharmacol 2010;640:129-38.
20. Wang J, Jiang Q, Wan L, et al. Sodium tanshinone IIA sulfonate inhibits canonical transient receptor potential expression in pulmonary arterial smooth muscle from pulmonary hypertensive rats. Am J Respir Cell Mol Biol 2013;48:125-34.
21. Huang YF, Liu ML, Dong MQ, et al. Effects of sodium tanshinone II A sulphonate on hypoxic pulmonary hypertension in rats in vivo and on Kv2.1 expression in pulmonary artery smooth muscle cells in vitro. J Ethnopharmacol 2009;125:436-43.